Physicians' Academy for Cardiovascular Education
The OCEANIC-AF study will be stopped early due to a lack of efficacy. The study investigates the effects of FXIa inhibitor asundexian compared to apixaban on the risk of stroke and systemic embolism in patients with AF at risk of stroke.
AHA 2023 In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.
AHA 2023 Apixaban reduced stroke or systemic embolism in patients with subclinical atrial fibrillation compared with aspirin in the ARTESIA trial. Apixaban increased the risk of major bleeding but there was no increase intracranial bleeding or fatal bleeding.
AHA 2023 What are the findings of a phase 2 trial in which two doses of the FXI/XIa inhibitor abelacimab were compared with rivaroxaban with regard to the safety outcome of bleeding in patients with AF?
In a secondary analysis of the EMPEROR-Preserved trial, the beneficial effects of empagliflozin on cardiovascular and renal outcomes were consistent in patients with HFpEF regardless of AF.
A meta-analysis showed that breast cancer survivors have an increased risk of CV death, HF, and AF, but not of CAD, MI, or ischemic stroke, compared with the general population.
ESC Congress 2023 In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.
The AZALEA-TIMI 71 trial, in which the efficacy of the factor XI/XIa inhibitor abelacimab was compared with rivaroxaban in patients with AF at moderate-to-high risk of stroke, has been stopped early due to an overwhelming reduction in bleeding.
ESC Congress 2023 An analysis of the RIVER trial showed that among patients with atrial fibrillation or flutter and a bioprosthetic mitral valve, patients with rheumatic heart disease did not have an increased risk of thrombotic and bleeding events.
ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.
ESC Congress 2023 In the FRAIL-AF trial, frail older adults with AF were randomized to switch from a VKA to a DOAC or to continue using a VKA. Linda Joosten talks about the unexpected results of this trial.
ESC Congress 2023 The FRAIL-AF trial showed that frail older patients with AF who switched from VKA to a DOAC had a 69% higher risk of bleeding, compared with patients who continued using VKA. There was no difference between DOACs and VKA in stroke reduction in this patient population.
